

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



Tweyongyere, R; Mawa, PA; Emojong, NO; Mpairwe, H; Jones, FM; Duong, T; Dunne, DW; Vennervald, BJ; Katunguka-Rwakishaya, E; Elliott, AM (2009) Effect of praziquantel treatment of *Schistosoma mansoni* during pregnancy on intensity of infection and antibody responses to schistosome antigens: results of a randomised, placebo-controlled trial. *BMC infectious diseases*, 9. ISSN 1471-2334 DOI: <https://doi.org/10.1186/1471-2334-9-32>

Downloaded from: <http://researchonline.lshtm.ac.uk/5304/>

DOI: [10.1186/1471-2334-9-32](https://doi.org/10.1186/1471-2334-9-32)

Usage Guidelines

Please refer to usage guidelines at <http://researchonline.lshtm.ac.uk/policies.html> or alternatively contact researchonline@lshtm.ac.uk.

Available under license: <http://creativecommons.org/licenses/by/2.5/>

Research article

Open Access

Effect of praziquantel treatment of *Schistosoma mansoni* during pregnancy on intensity of infection and antibody responses to schistosome antigens: results of a randomised, placebo-controlled trial

Robert Tweyongyere*^{1,2}, Patrice A Mawa², Nicholas O Emojong², Harriet Mpairwe², Frances M Jones³, Trinh Duong⁴, David W Dunne³, Birgitte J Vennervald⁵, Eli Katunguka-Rwakishaya¹ and Alison M Elliott^{2,4}

Address: ¹Faculty of Veterinary Medicine, Makerere University, Kampala, Uganda, ²Medical Research Council/Uganda Virus Research Institute-Uganda Research Unit on AIDS, Kampala, Uganda, ³Department of Pathology, University of Cambridge, Cambridge, UK, ⁴London School of Hygiene and Tropical Medicine, London, UK and ⁵DBL-Centre for Health Research and Development, Department of Disease Biology, University of Copenhagen, Copenhagen, Denmark

Email: Robert Tweyongyere* - tmrobert966@gmail.com; Patrice A Mawa - Pratice.Mawa@mrcuganda.org; Nicholas O Emojong - Nicholas.Emojong@mrcuganda.org; Harriet Mpairwe - Harriet.Mpairwe@mrcuganda.org; Frances M Jones - fmj20@cam.ac.uk; Trinh Duong - Trinh.Duong@lshrm.ac.uk; David W Dunne - dd@mole.bio.cam.ac.uk; Birgitte J Vennervald - bjv@life.ku.dk; Eli Katunguka-Rwakishaya - erkatunguka@vetmed.mak.ac.ug; Alison M Elliott - Alison.tom@infocom.co.ug

* Corresponding author

Published: 18 March 2009

Received: 26 December 2008

BMC Infectious Diseases 2009, 9:32 doi:10.1186/1471-2334-9-32

Accepted: 18 March 2009

This article is available from: <http://www.biomedcentral.com/1471-2334/9/32>

© 2009 Tweyongyere et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: Praziquantel treatment of schistosomiasis during pregnancy was only recommended in 2002; hence the effects of treatment during pregnancy are not fully known. We have therefore evaluated the effects on infection intensity and the immunological effects of praziquantel treatment against *Schistosoma mansoni* during pregnancy, compared with treatment after delivery.

Methods: A nested cohort of 387 *Schistosoma mansoni* infected women was recruited within a larger trial of de-worming during pregnancy. Women were randomised to receive praziquantel or placebo during pregnancy. All women were treated after delivery. Infection intensity after treatment was assessed by a single Kato-Katz examination of stool samples with duplicate slides and categorised as undetected, light (1–99 eggs per gram (epg)), moderate (100–399 epg) or heavy (≥ 400 epg). Antibodies against *S. mansoni* worm and egg antigens were measured by ELISA. Results were compared between women first treated during pregnancy and women first treated after delivery.

Results: At enrolment, 252 (65.1%) of the women had light infection (median (IQR) epg: 35 (11, 59)), 75 (19.3%) moderate (median (IQR) epg: 179 (131, 227)) and 60 (15.5%) had heavy infection (median (IQR) epg: 749 (521, 1169)) with *S. mansoni*. At six weeks after praziquantel treatment during pregnancy *S. mansoni* infection was not detectable in 81.9% of the women and prevalence and intensity had decreased to 11.8% light, 4.7% moderate and 1.6% heavy a similar reduction when compared with those first treated after delivery (undetected (88.5%), light (10.6%), moderate (0.9%) and heavy (0%), $p = 0.16$). Parasite specific antibody levels were lower during pregnancy than

after delivery. Praziquantel treatment during pregnancy boosted anti-worm IgG isotypes and to a lesser extent IgE, but these boosts were less pronounced than in women whose treatment was delayed until after delivery. Praziquantel had limited effects on antibodies against egg antigens.

Conclusion: *S. mansoni* antigen-specific antibody levels and praziquantel-induced boosts in antibody levels were broadly suppressed during pregnancy, but this was not associated with major reduction in the efficacy of praziquantel. Long-term implications of these findings in relation to resistance to re-infection remain to be explored.

Trial registration: International Standard Randomised Controlled Trial Number for the current study: ISRCTN32849447 <http://www.controlled-trials.com/ISRCTN32849447/elliott>

Background

Praziquantel treatment of human schistosomiasis during pregnancy and lactation was avoided [1] from the time it became available, in 1979, until an informal consultation by the World Health Organisation in 2002. It was then recommended that pregnant and lactating women with schistosomiasis should be treated [2,3]. This recommendation was based on animal studies, as well as case reports of inadvertent or necessary treatment of pregnant women, which showed no evidence of adverse effects. However, since the benefits and risks of treatment during pregnancy had not been studied, a WHO scientific working group in 2005 called for randomised, placebo-controlled trials of treatment during pregnancy for all species of human schistosomes in both low and high transmission areas [4]. We here report findings from the first such trial (Elliott et al., 2007). In particular, we describe the results of a sub-study designed to examine the immunological effects of treating *Schistosoma mansoni* with praziquantel during pregnancy, compared with the effects of treatment after delivery.

Praziquantel is the drug of choice against all schistosome infections and has shown reliable therapeutic effectiveness. Regular treatment of populations in endemic areas alleviates severe morbidity [5]. One factor that may influence the efficacy of praziquantel is the immune status of the host. Studies have demonstrated that the mode of action of praziquantel involves unique synergy with the host immune responses: praziquantel-induced damage of surface membranes of schistosomes [6-8] exposes the antigens for immune attack [9,10] and, in particular, there is evidence that the efficacy of praziquantel against *S. mansoni* is to some extent dependent on antibodies [11-14]. At the same time, praziquantel treatment of *S. mansoni* causes a boost in parasite-specific antibody responses [15] and there is evidence that some boosts in antibody levels, particularly in immunoglobulin (Ig)E production, may be related to resistance to re-infection [16,17]. However, immune responses are normally altered during pregnancy [18] to allow foetal allograft retention [19-22] and it is therefore of concern that praziquantel treatment dur-

ing pregnancy may be less effective than treatment in non-pregnant women. For this reason, within our study of the effect of praziquantel during pregnancy on immune responses to schistosome antigens, we have also examined the effects of praziquantel on the intensity of *S. mansoni* infection and have compared effects of treatment during pregnancy with effects of treatment after delivery. We have previously reported that schistosome antigen-specific cytokine responses were suppressed during pregnancy and that boosts in cytokine responses after praziquantel treatment were smaller during pregnancy than after delivery, in a sub-group for whom data on cytokine responses was available [23]. We here report effects of praziquantel treatment during pregnancy on *S. mansoni* intensity and on anti-schistosome antibody responses.

Methods

Study design

A nested cohort of 387 pregnant women having schistosomiasis mansoni was enrolled within a larger mother and baby cohort study on "the impact of helminths on the response to immunization and on susceptibility to infectious diseases in childhood in Uganda" (ISRCTN 32849447; <http://www.controlled-trials.com/ISRCTN32849447/elliott>) [24]. The study was a randomised, double-blind placebo-controlled trial using praziquantel versus placebo and albendazole versus placebo during pregnancy in a 2 × 2 factorial design. Details of the larger cohort and nested cohort have been described [23,24]. Briefly: consenting mothers gave blood for investigations including malaria parasitology, HIV serology and immunological assays, and were asked to provide stool samples for examination for helminth ova. After submission of the first stool sample, they were randomised to receive a single dose of either praziquantel (40 mg/kg), or placebo and albendazole (400 mg) or placebo. At six weeks after delivery all mothers received praziquantel and albendazole treatment. Follow-up samples were obtained at six weeks post-enrolment (while still pregnant), six weeks after delivery (before post-delivery treatment) and twelve weeks after delivery (six weeks after post-delivery treatment). Figure one is a schematic presen-

tation of the follow-up time points, the respective interventions, and samples collected.

Recruitment of the larger cohort was between April 2003 and November 2005, but recruitment to the nested cohort, which constituted women who had *S. mansoni* ova in stool, and which included additional, six-week post-treatment follow up visits, began in November 2003.

Ethical consideration

Informed consent was obtained from each participant to enrol in the study and provide samples as described previously [24]. Ethical clearance for the study was obtained from the Science and Ethics Committee of Uganda Virus Research Institute – Ministry of Health, the Uganda National Council for Science and Technology and the London School of Hygiene and Tropical Medicine.

Parasitological diagnosis

A single stool sample per individual was examined for *S. mansoni* ova and other helminth ova including hookworm by duplicate Kato-Katz thick smears [25] at respective time points. *S. mansoni* infection intensity was expressed in eggs per gram (epg) of stool and categorised as light (1–99 epg), moderate (100–399 epg) or heavy (≥ 400 epg).

Parasite antigens

Antigen extracts of *S. mansoni* adult worm (SWA) and egg (SEA) were prepared as previously described [10,26].

Assay of antibodies against schistosome

Immunoglobulins (Ig) G1, G2, G3, G4, E and M against SWA and IgG1, IgG2, IgG3, IgG4 and IgE against SEA were measured in the plasma of the subjects in duplicates per sample using an ELISA method as described elsewhere [27,28]. Briefly: flat bottom 96-well styrene microtitre - 9205 plates (Thermo Labsystems, USA) were coated 100 μ l per well with SWA at 8 μ g/ml or SEA at 2.4 μ g/ml and incubated overnight at 4°C. The standard positive pool (prepared and optimised in-house at Department of Pathology, Cambridge University) was serially diluted and added in columns 1 and 2 of the plate and formed the standard curve for quantification of antibodies. Biotinylated mouse anti-human monoclonal antibodies used for the detection were obtained from BD Pharmingen (San Diego USA), except IgG3 which was obtained from Zymed (S. San Francisco, USA). Poly-HRP-streptavidin conjugate (Sanquin, Netherlands) was added at 1/4000 dilution. The plates were developed with OPD substrate and the reaction stopped by addition of 25 μ l per well of 2 M sulphuric acid on observing the colour change. Optical densities (ODs) were recorded into a data file in DeltaSOFT II (BioMetalics, Inc USA) micro-plate analysis software programme and exported into Microsoft excel

program. The ODs were interpolated into absolute concentration using Stata 5.0 (StataCorp, USA) generated standard curves. The sensitivity of the test was the lowest standard concentration above which levels were detectable.

Statistical analysis

Data was entered in Microsoft Excel (Microsoft, USA) and imported into Stata (version 9 StataCorp, USA) for statistical analysis.

To assess the effect of pregnancy on the praziquantel-induced reduction in infection intensity, a simple table and χ^2 test was used to compare infection intensity categories at six weeks post treatment between women who were first treated during pregnancy (infection intensity at six weeks post-enrolment among praziquantel group) and those who were first treated at six weeks after delivery (infection intensity at 12 weeks after delivery among the initially placebo group).

Some antibody isotypes were detectable in less than 50% of the individuals, so antibody data was initially analysed as binary variables dichotomised according to whether the antibody was detectable or not. Subsequent analyses with the levels treated as quantitative variables were found to be more informative and are therefore presented, with results from both approaches consistent. Since the data was not normally distributed, non parametric statistical tests were used, except when comparing the boosts in antibody data that approached a normal distribution, when regression analysis was applied.

The analysis of schistosome antigen-specific antibodies had three main objectives:

1. To examine effect of pregnancy on antibody levels. Among the placebo group, antibody levels at enrolment and six weeks post-enrolment were compared with antibody levels at six weeks after delivery using Wilcoxon signed rank test.
2. To assess the effect of praziquantel treatment during pregnancy. First, within the group treated during pregnancy, antibody levels before and after praziquantel treatment were compared using Wilcoxon signed rank test. Then, levels at six weeks post-enrolment were compared between the placebo and praziquantel groups using Wilcoxon rank sum (Mann-Whitney) test.
3. To examine the influence of pregnancy on the praziquantel-induced boost in antibody levels at six weeks post-treatment. Initially the influence of infection intensity at enrolment and pre-treatment antibody levels on the boost in the antibody levels were explored using spearman's cor-

relation analysis. The change (boost) in antibody levels during pregnancy among women first treated during pregnancy was compared with the change after delivery among women first treated after delivery using linear regression based on $\log_{10}(\text{antibody concentration}+1)$.

Results

Between November 2003 and November 2005, 2208 women were recruited to the larger cohort of whom 387 (17.5%) had stool samples positive for *Schistosoma mansoni*; of these 186 women received praziquantel and 201 women received placebo. Due to some participants missing scheduled appointments or insufficient amounts of plasma samples to repeat failed antibody assays the numbers analysed for particular time points varied (figure 1). Characteristics of the women at enrolment, including intensity of schistosome infection, levels of antibodies against schistosome antigens and prevalence of co-infections such as hookworm, *P. falciparum* and HIV, were similar among the praziquantel and placebo groups (additional file 1). Except for *S. mansoni* infection intensity, none of these factors was associated with schistosome antigen-specific antibody levels at enrolment (data not shown). There were positive correlations between *S. mansoni* infection intensity and levels of IgG1 ($p < 0.001$), IgG2 ($p = 0.01$), IgG4 ($p < 0.001$) and IgE ($p < 0.001$) against SWA and IgG4 against SEA while there were negative correlations between *S. mansoni* infection intensity and levels of IgG1 ($p = 0.005$), IgG2 ($p < 0.001$) and IgG3 ($p = 0.005$) against SEA.

The effect of praziquantel on *S. mansoni* infection intensity was similar when given during pregnancy or after delivery

Among women randomised to praziquantel during pregnancy, 104/127 (81.9%) were negative for *Schistosoma mansoni* at six weeks post-treatment while 11.8%, 4.7% and 1.6% still had light, moderate and heavy infection respectively. In the placebo group who were later treated after delivery, 100/113 (88.5%) were negative while 10.6% and 0.9% still had light and moderate infection respectively at six weeks post-treatment, while none had heavy infection. Thus although the residual intensity was slightly higher in the group treated during pregnancy, this effect was small ($p = 0.16$). Further, there was no evidence of an effect of gestational age at the time of treatment among those treated during pregnancy (data not shown). Albendazole did not influence the effects of praziquantel treatment against *S. mansoni* nor did praziquantel influence the effects of albendazole against hookworm (data not shown).

Levels of antibodies against SWA and SEA are reduced during pregnancy

Among the placebo group, levels of antibodies against SWA (figure 2A) and SEA (figures 3A), at enrolment and

six weeks post-enrolment during pregnancy were consistently lower than at six weeks after delivery; and this effect was strong at enrolment for IgG1 ($p < 0.001$), IgG2 ($p = 0.018$), IgG4 ($p = 0.002$) and IgE ($p < 0.001$) against SWA, and for IgG1 ($p = 0.014$) and IgG4 ($p = 0.032$) against SEA and at six weeks post-enrolment for IgG1 ($p < 0.001$), IgG2 ($p = 0.005$), IgG3 ($p = 0.012$), IgG4 ($p = 0.001$) and IgE ($p = 0.018$) against SWA, and IgG1 ($p = 0.001$), IgG3 ($p = 0.009$) and IgG4 ($p = 0.008$) against SEA.

Praziquantel treatment during pregnancy causes boosts in levels of antibodies against SWA as well as IgG3 and IgE against SEA

Among the women who received praziquantel at enrolment, there was a significant boost in levels of IgG1 ($p < 0.001$), IgG2 ($p < 0.001$), IgG3 ($p = 0.011$) and IgG4 ($p < 0.001$) against SWA at six weeks post-treatment (figure 2B). When antibody levels at six weeks post-enrolment were compared between the placebo and the praziquantel groups, the levels of antibodies against SWA were higher in the praziquantel group than in the placebo group ($p < 0.001$ for IgG1-3, $p = 0.034$ for IgG4, $p = 0.049$ for IgE and $p = 0.013$ for IgM). Levels of IgE against SWA did not show significant boost at six weeks post-treatment, but at six weeks after delivery IgE levels were significantly higher than pre-treatment ($p < 0.001$) and six weeks post-treatment ($p = 0.006$), and the level among women treated during pregnancy was again higher than among those who received placebo ($p = 0.018$). IgG subtypes and IgM showed no further increase after delivery.

In contrast, boosts in antibodies against SEA were only seen for IgG3 (p -value= 0.02) and IgE (p -value = 0.043), with levels at six weeks post-treatment higher than pre-treatment levels (figure 3B). When antibody levels at six weeks post-enrolment were compared between the placebo and praziquantel groups, levels of IgG2 ($p = 0.006$), IgG3 and IgE ($p < 0.001$) against SEA were higher among the praziquantel group than the placebo group. On the other hand, the level of IgG4 against SEA showed significant decline between enrolment and six weeks post-treatment ($p = 0.02$) and at six weeks post-enrolment the levels were not significantly different between the placebo and praziquantel group.

Pregnancy causes suppression of praziquantel induced-boost in levels of some antibodies against SWA and SEA

Antibody levels in the group randomised to placebo and who received initial praziquantel treatment at six weeks after delivery were examined at 6 weeks post-treatment to assess the effect of treating non-pregnant women (figures 2A and 3A). Significant boosts in antibodies against SWA ($p < 0.001$ for IgG1-4, and IgM) as well as IgG2 ($p < 0.001$) and IgE ($p = 0.006$) against SEA were observed at six weeks after post-delivery treatment. As observed with treatment during pregnancy, levels of IgG4 against SEA (p




Figure 1
Flow diagram showing the scheduled time points of the study and samples assessed at the respective time points. *Women who missed attending or providing samples at some time points were allowed to participate at subsequent follow-up time points.




Figure 2
Plasma levels of antibodies against *S. mansoni* adult worm antigen (SWA) and effect of praziquantel treatment during pregnancy or after delivery on the antibody levels. The y-axis shows \log_{10} (antibody concentrations (pg/ml)+1). The x-axis shows time points: enrolment (Enrol), 6 weeks post-enrolment (6 wks PE), 6 weeks after delivery (6 wksAD) and 12 weeks after delivery (12 wks AD). The arrows indicate the intervention time points when the women were given either placebo (black) or praziquantel treatment (red). The box plots in column A are for participants who received placebo at enrolment during pregnancy and received praziquantel treatment for the first time six weeks after delivery. The box plots in column B are for participants who received praziquantel treatment during pregnancy. P values are given for the comparison in boost in antibody levels for praziquantel given for the first time during pregnancy vs after delivery, adjusted for pre-treatment antibody levels, *S. mansoni* infection intensity at enrolment and concurrent albendazole therapy. P values for other comparisons are given in the text.

= 0.007) significantly declined following post-delivery praziquantel treatment.

Comparing post-treatment antibody levels by timing of treatment showed that the boosts in antibody levels were generally lower for treatment during pregnancy than for treatment after delivery (additional file 2). As well as absolute antibody levels, boosts in antibody levels against SWA tended to show a positive association with infection intensity at enrolment (data not shown). After adjusting for the pre-treatment antibody levels, infection intensity at enrolment and albendazole treatment, the post-treatment boosts remained lower for the women first treated during pregnancy than those first treated after delivery, particularly significant for IgG3, IgG4 and IgM against SWA and for IgG1 and IgG2 against SEA (additional file 2).

Discussion

This study suggests that praziquantel treatment against *S. mansoni* during pregnancy has similar efficacy as praziquantel treatment in non-pregnant women, despite the presence of lower levels of anti-schistosome antibodies and tendency to reduced boosting of both antibody and cytokine responses observed during pregnancy.

In assessing effects on *S. mansoni* infection intensity, the chief limitation of this study was the use of a single stool sample to determine prevalence and intensity of *S. mansoni* after treatment. A single stool sample has low sensitivity in detection of helminth infections [29-31], hence the prevalence will have been underestimated and estimates of intensity will have been imprecise. However, since comparisons were made between randomised groups, these limitations are likely to have applied similarly at follow up in both groups; the proportion apparently "cured" will have been exaggerated in both groups, but the comparison remains valid, suggesting little difference in the effect of treatment during pregnancy or after delivery.

In this study, alterations in the levels of schistosome antigen-specific antibodies during pregnancy, as well as the effect of praziquantel treatment during pregnancy on the antibody levels, were elucidated. Levels of IgG1, IgG2, IgG3, IgG4 and IgE against SWA and SEA, were generally low during pregnancy. These findings accord those of Novato-Silva and colleagues [32] showing that antibody levels against adult schistosome worm antigens declined with progression of pregnancy. These observations are contrary to other reports on antibodies to non-schistosome antigens showing that humoral immune responses are not affected by progression of pregnancy [19,33]. There is normally an increase in plasma and blood volume during pregnancy [34] which is apparent at six weeks,

and is maximum (40–50%) between 32–36 weeks, of pregnancy [34,35]. Although this dilution effect of increased blood volume of pregnancy was not examined in our study, it could potentially explain the low antibody levels during pregnancy rather than a decline in the antibody responses *per se*.

Praziquantel treatment during pregnancy caused a boost in antibody levels against SWA and to a limited extent SEA; although a significant drop in levels of IgG4 against SEA was observed. These boosts in antibodies at six weeks post-treatment were consistent with those observed at five weeks post-treatment [36], three months post-treatment [37] and at six months post-treatment [27] among *S. mansoni* infected non-pregnant individuals in endemic areas. Similar increases in antibodies were recently reported following treatment among non-pregnant adults from a new focus of *S. mansoni* infection [38]. The decline in the level of IgG4 against SEA following praziquantel treatment was also consistent with findings reported among non-pregnant individuals [37,39]. The boost in IgE against SWA was less marked than for other antibodies against SWA. It is possible that six weeks after treatment could have been too short a follow-up time to observe a significant boost in levels of IgE against SWA. This was consistent with other studies where post-treatment levels of IgE against SWA were not significantly boosted at three weeks [26] and five weeks [36], following treatment, suggesting that this particular isotype remains relatively stable over time among adults in *S. mansoni* endemic areas.

Although boosts in schistosome antigen-specific antibody response were observed during pregnancy, these were generally lower, and post-treatment antibody levels were lower, compared with treatment after delivery. However, in spite of this, the data did not show evidence that pregnancy and having lower boosts in schistosome antigen specific antibody isotypes had any significant impact on the efficacy of praziquantel treatment against *S. mansoni*. Suppression of the boosts in antibodies during pregnancy may, however, have effects on resistance to reinfection. Due to limited follow-up time and since all the women received praziquantel treatment after delivery, the impact of treatment during pregnancy on susceptibility to reinfection after treatment was not explored. Therefore, further studies might be necessary to examine the long-term implications of the suppression of boosts in some of the antibody isotypes following treatment during pregnancy.

Conclusion

This study, the first to examine the impact of praziquantel treatment during pregnancy, has shown that *S. mansoni* antigen-specific antibody levels and praziquantel-induced boosts in the antibody levels are broadly low during pregnancy, but that this is not associated with any major




Figure 3
Plasma levels of antibodies against *S. mansoni* egg antigen (SEA) and effect of praziquantel treatment during pregnancy or after delivery on the antibody levels. The y-axis shows \log_{10} (antibody concentrations (pg/ml)+1). The x-axis shows time points: enrolment (Enrol), 6 weeks post-enrolment (6 wks PE), 6 weeks after delivery (6 wksAD) and 12 weeks after delivery (12 wks AD). The arrows indicate the intervention time points when the women were given either placebo (black) or praziquantel treatment (red). The box plots in column A are for participants who received placebo at enrolment during pregnancy and received praziquantel treatment for the first time six weeks after delivery. The box plots in column B are for participants who received praziquantel treatment during pregnancy. P values are given for the comparison in boost in antibody levels for praziquantel given for the first time during pregnancy vs after delivery, adjusted for pre-treatment antibody levels, *S. mansoni* infection intensity at enrolment and concurrent albendazole therapy. P values for other comparisons are given in the text.

reduction in the efficacy of praziquantel in the treatment of light to moderate intensity *S. mansoni* infections: a result that is reassuring from a public health perspective. Effects of pregnancy on the response to praziquantel among populations with higher *S. mansoni* infection intensities, and among women with *S. haematobium* or *S. japonicum*, and the long-term implications of these findings, particularly in relation to resistance to re-infection, remain to be explored.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

RT participated in designing the study, carried out the immunoassays, did the data analysis, drafted the manuscript and coordinated writing the manuscript. PMA participated in the immunoassays. NOE participated in the parasitological analysis of stool samples. HP: participated in collection of the samples and coordination of participants. FMJ participated in the immunoassays. TD participated in the data analysis. DWD participated in designing the study and writing the manuscript. BJV participated in designing the study and writing the manuscript. EKR contributed in conducting the study. AME conceived the idea of the study, participated in designing the study, data analysis and coordinated writing of the manuscript. All the authors read and approved the final manuscript.

Additional material

Additional file 1

Table 1. Comparison of characteristics at enrolment between the praziquantel and placebo groups

Click here for file

[<http://www.biomedcentral.com/content/supplementary/1471-2334-9-32-S1.doc>]

Additional file 2

Table 2. Comparison of the boost in levels of antibodies against SWA and SEA at six weeks following praziquantel treatment during pregnancy or after delivery

Click here for file

[<http://www.biomedcentral.com/content/supplementary/1471-2334-9-32-S2.doc>]

Acknowledgements

We thank members of the teams that were involved in the study: the Entebbe Mother and Baby Study (EMaBS) women participants, staff of EMaBS and Entebbe Grade B Hospital maternity ward. In particular we are grateful to the EMABS technicians, Kizito D., Kesande B., Lutangira J.E. and Namujju P. who participated in the collection, initial preparation and storage of the samples for the study. We thank the Cambridge University Schistosomiasis Immunology Group. We thank Makerere University, Cambridge University, MRC/UVRI Uganda Research Unit on AIDS and Entebbe Hospi-

tal for institutional support. The Wellcome Trust funded the study through a senior fellowship held by AME (grant number 064693), Makerere University School of Graduate Studies and DBL-Institute for Health Research and Development funded the study through PhD research grant to RT. The Association of Commonwealth Universities supported this study through a doctoral scholarship to RT.

References

1. WHO: **Report of the WHO informal consultation on monitoring drug efficacy in the control of schistosomiasis and intestinal nematodes; 8–10 July 1998.** Geneva: WHO; 1999.
2. Allen HE, Crompton DW, de Silva N, LoVerde PT, Olds GR: **New policies for using anthelmintics in high risk groups.** *Trends Parasitol* 2002, **18(9)**:381-382.
3. WHO: **Report of the WHO Informal Consultation on the use of praziquantel during pregnancy/lactation and albendazole/mebendazole in children under 24 months; 8–9 April 2002.** Geneva: WHO; 2003:49.
4. WHO: **Report of the scientific working group meeting on schistosomiasis; 14–16 November 2005.** Geneva: WHO-TDR; 2006:114.
5. WHO: **Preventive chemotherapy in human helminthiasis: A manual for health professionals and programme managers.** Geneva: WHO; 2006.
6. Becker B, Mehlhorn H, Andrews P, Thomas H: **Scanning and transmission electron microscope studies on the efficacy of praziquantel on *Hymenolepis nana* (Cestoda) in vitro.** *Z Parasitenkd* 1980, **61(2)**:121-133.
7. Becker B, Mehlhorn H, Andrews P, Thomas H, Eckert J: **Light and electron microscopic studies on the effect of praziquantel on *Schistosoma mansoni*, *Dicrocoelium dendriticum*, and *Fasciola hepatica* (Trematoda) in vitro.** *Z Parasitenkd* 1980, **63(2)**:113-128.
8. Shuhua X, Binggui S, Chollet J, Tanner M: **Tegumental changes in adult *Schistosoma mansoni* harboured in mice treated with praziquantel enantiomers.** *Acta Trop* 2000, **76(2)**:107-117.
9. Roberts SM, Wilson RA, Ouma JH, Kariuki HC, Koech D, arap Siongok TK, Sturrock RF, Butterworth AE: **Immunity after treatment of human schistosomiasis mansoni quantitative and qualitative antibody responses to tegumental membrane antigens prepared from adult worms.** *Trans R Soc Trop Med Hyg* 1987, **81(5)**:786-793.
10. Fallon PG, Cooper RO, Probert AJ, Doenhoff MJ: **Immune-dependent chemotherapy of schistosomiasis.** *Parasitology* 1992, **105(Suppl)**:S41-48.
11. Brindley PJ, Sher A: **The chemotherapeutic effect of praziquantel against *Schistosoma mansoni* is dependent on host antibody response.** *J Immunol* 1987, **139(1)**:215-220.
12. Doenhoff MJ, Sabah AA, Fletcher C, Webbe G, Bain J: **Evidence for an immune-dependent action of praziquantel on *Schistosoma mansoni* in mice.** *Trans R Soc Trop Med Hyg* 1987, **81(6)**:947-951.
13. Brindley PJ, Strand M, Norden AP, Sher A: **Role of host antibody in the chemotherapeutic action of praziquantel against *Schistosoma mansoni*: identification of target antigens.** *Mol Biochem Parasitol* 1989, **34(2)**:99-108.
14. Brindley PJ, Sher A: **Immunological involvement in the efficacy of praziquantel.** *Exp Parasitol* 1990, **71(2)**:245-248.
15. Walter K, Fulford AJ, McBeath R, Joseph S, Jones FM, Kariuki HC, Mwatha JK, Kimani G, Kabatereine NB, Vennervald BJ, et al.: **Increased human IgE induced by killing *Schistosoma mansoni* in vivo is associated with pretreatment Th2 cytokine responsiveness to worm antigens.** *J Immunol* 2006, **177(8)**:5490-5498.
16. Rihet P, Demeure CE, Bourgeois A, Prata A, Dessein AJ: **Evidence for an association between human resistance to *Schistosoma mansoni* and high anti-larval IgE levels.** *Eur J Immunol* 1991, **21(11)**:2679-2686.
17. Dunne DW, Butterworth AE, Fulford AJ, Ouma JH, Sturrock RF: **Human IgE responses to *Schistosoma mansoni* and resistance to reinfection.** *Mem Inst Oswaldo Cruz* 1992, **87(Suppl 4)**:99-103.
18. Gehrz RC, Christianson WR, Linner KM, Conroy MM, McCue SA, Balfour HH Jr: **A longitudinal analysis of lymphocyte prolifera-**

- itive responses to mitogens and antigens during human pregnancy. *Am J Obstet Gynecol* 1981, **140(6)**:665-670.
19. Lederman MM: **Cell-mediated immunity and pregnancy.** *Chest* 1984, **86(3 Suppl)**:65-9S.
 20. Robertson SA: **Control of the immunological environment of the uterus.** *Rev Reprod* 2000, **5(3)**:164-174.
 21. Guleria I, Sayegh MH: **Maternal acceptance of the fetus: true human tolerance.** *J Immunol* 2007, **178(6)**:3345-3351.
 22. Ling B, Yao FQ, Zhou Y, Chen ZZ, Shen GD, Zhu YY: **Cell-mediated immunity imbalance in patients with intrahepatic cholestasis of pregnancy.** *Cell Mol Immunol* 2007, **4(1)**:71-75.
 23. Tweyongyere R, Mawa PA, Ngom-Wegi S, Ndibazza J, Duong T, Vennervald BJ, Dunne DW, Katunguka-Rwakishaya E, Elliott AM: **Effect of Praziquantel Treatment during Pregnancy on Cytokine Responses to Schistosome Antigens: Results of a Randomized, Placebo-Controlled Trial.** *J Infect Dis* 2008, **198(12)**:1870-1879.
 24. Elliott AM, Kizza M, Quigley MA, Ndibazza J, Nampijja M, Muhangi L, Morison L, Namujju PB, Muwanga M, Kabatereine N, et al.: **The impact of helminths on the response to immunization and on the incidence of infection and disease in childhood in Uganda: design of a randomized, double-blind, placebo-controlled, factorial trial of deworming interventions delivered in pregnancy and early childhood [ISRCTN32849447].** *Clin Trials* 2007, **4(1)**:42-57.
 25. Katz N, Chaves A, Pellegrino J: **A simple device for quantitative stool thick-smear technique in Schistosomiasis mansoni.** *Rev Inst Med Trop Sao Paulo* 1972, **14(6)**:397-400.
 26. Fitzsimmons CM, Joseph S, Jones FM, Reimert CM, Hoffmann KF, Kazibwe F, Kimani G, Mwatha JK, Ouma JH, Tukahebwa EM, et al.: **Chemotherapy for schistosomiasis in Ugandan fishermen: treatment can cause a rapid increase in interleukin-5 levels in plasma but decreased levels of eosinophilia and worm-specific immunoglobulin E.** *Infect Immun* 2004, **72(7)**:4023-4030.
 27. Dunne DW, Butterworth AE, Fulford AJ, Kariuki HC, Langley JG, Ouma JH, Capron A, Pierce RJ, Sturrock RF: **Immunity after treatment of human schistosomiasis: association between IgE antibodies to adult worm antigens and resistance to reinfection.** *Eur J Immunol* 1992, **22(6)**:1483-1494.
 28. Webster M, Libranda-Ramirez BD, Aligui GD, Olveda RM, Ouma JH, Kariuki HC, Kimani G, Olds GR, Fulford AJ, Butterworth AE, et al.: **The influence of sex and age on antibody isotype responses to Schistosoma mansoni and Schistosoma japonicum in human populations in Kenya and the Philippines.** *Parasitology* 1997, **114(Pt 4)**:383-393.
 29. Utzinger J, Booth M, N'Goran EK, Muller I, Tanner M, Lengeler C: **Relative contribution of day-to-day and intra-specimen variation in faecal egg counts of Schistosoma mansoni before and after treatment with praziquantel.** *Parasitology* 2001, **122(Pt 5)**:537-544.
 30. Brown M, Bukusuba J, Hughes P, Nakiyingi J, Watera C, Elliott A, Whitworth J: **Screening for intestinal helminth infestation in a semi-urban cohort of HIV-infected people in Uganda: a combination of techniques may enhance diagnostic yield in the absence of multiple stool samples.** *Trop Doct* 2003, **33(2)**:72-76.
 31. Enk MJ, Lima AC, Drummond SC, Schall VT, Coelho PM: **The effect of the number of stool samples on the observed prevalence and the infection intensity with Schistosoma mansoni among a population in an area of low transmission.** *Acta Trop* 2008, **108(2-3)**:222-228.
 32. Novato-Silva E, Gazzinelli G, Colley DG: **Immune responses during human schistosomiasis mansoni. XVIII. Immunologic status of pregnant women and their neonates.** *Scand J Immunol* 1992, **35(4)**:429-437.
 33. Weinberg ED: **Pregnancy-associated depression of cell-mediated immunity.** *Rev Infect Dis* 1984, **6(6)**:814-831.
 34. Hytten F: **Blood volume changes in normal pregnancy.** *Clin Haematol* 1985, **14(3)**:601-612.
 35. Williams D: **Physiological changes of normal pregnancy.** In *Oxford Textbook of Medicine Volume 2*. 4th edition. Edited by: Warrell AD, Cox MT, Firth DJ, Benz JEJ. Oxford: Oxford University Press; 2003:383-385.
 36. Joseph S, Jones FM, Laidlaw ME, Mohamed G, Mawa PA, Namujju PB, Kizza M, Watera C, Whitworth JA, Dunne DW, et al.: **Impairment of the Schistosoma mansoni-specific immune responses elicited by treatment with praziquantel in Ugandans with HIV-1 coinfection.** *J Infect Dis* 2004, **190(3)**:613-618.
 37. Satti MZ, Lind P, Vennervald BJ, Sulaiman SM, Daffalla AA, Ghalib HW: **Specific immunoglobulin measurements related to exposure and resistance to Schistosoma mansoni infection in Sudanese canal cleaners.** *Clin Exp Immunol* 1996, **106(1)**:45-54.
 38. Vereecken K, Naus CVW, Polman K, Scott JT, Diop M, Gryseels B, Kestens L: **Associations between specific antibody responses and resistance to reinfection in a Senegalese population recently exposed to Schistosoma mansoni.** *Trop Med Int Health* 2007, **12(3)**:431-444.
 39. Abd El-Aal AA, El-Arousy MH, El-Gendy AM, Tunkul Ael K, Ismail SA, El-Badry AA: **Early post-treatment immunoglobulin profile in human schistosomiasis.** *J Egypt Soc Parasitol* 2005, **35(1)**:167-180.

Pre-publication history

The pre-publication history for this paper can be accessed here:

<http://www.biomedcentral.com/1471-2334/9/32/prepub>

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

